Brand and Other Names:Egrifta
- Classes: Growth Hormone Releasing Factors
Dosing & Uses
Dosage Forms & Strengths
- 2mg/vial (1mg/mL solution after reconstituted)
2 mg SC qDay, preferably once daily
Inject into abdomen (avoid the navel or any scar tissue) and rotate injection site daily
Limitations of use
Long-term cardiovascular benefit and safety not studied
Not indicated for weight loss management (weight neutral effect)
There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking tesamorelin
Reconstitute lyophilized powder with supplied 2.1 mL of diluent
Mix by rolling the vial gently in your hands for 30 seconds
Do not shake
Unopened vial: Store refrigerated between 2-8°C (36-46°F) until the expiration date or below 25°C (77°F) for 3 months or until the expiration date, whichever occurs first
Protect from light
Do not freeze
Store reconstitution diluent (Sterile Water for Injection, USP), syringes, and needles at controlled room temperature of 20-25°C (68-77°F)
Do not freeze or refrigerate the reconstituted solution
Safety and efficacy not established
Should not be used in children with open epiphyses, among whom excess GH and IGF-I may result in linear growth acceleration and excessive growth
Serious - Use Alternative
Significant - Monitor Closely
Injection site reactions (up to 8.5%)
Extremity pain (6.1%)
Musculoskeletal pain and stiffness (1.7-1.8%)
Increased CPK (1.5%)
Carpal tunnel syndrome (1.5%)
Joint stiffness/swelling (1.1-1.5%)
Muscle spasms (1.1%)
Mental status changes
Upper respiratory tract infection
Hypersensitivity to tesamorelin or mannitol
Disruption of HP axis caused by hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma
Caution with history of nonmalignant neoplasms; preexisting malignancy should be inactive and treatment complete prior to initiating therapy
If hypersensitivity suspected, discontinue and provide immediate medical attention
Consider discontinuing with persistent elevations of IGF-I levels (eg, >3 SDS), particularly if efficacy response is not robust
Fluid retention may occur and may include edema, arthralgia, and carpal tunnel syndrome
Increased mortality with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure following treatment with pharmacologic amounts of growth hormone
May modulate CYP450-mediated antipyrine clearance
Not for use in children when epiphyses open because may cause excessive growth
Inhibits 11-beta-hydroxysteroid dehydrogenase type-1, a microsomal enzyme required for conversion of cortisone and prednisone to their active metabolites
Injections site reactions including irritation, erythema, pain, and bruising may occur; rotate site of injection to different areas of abdomen to reduce incidence of injection site reactions
May increase risk of development of diabetes due to glucose intolerance; evaluate glucose status prior to and during therapy
Not indicated for weight loss management
Pregnancy & Lactation
Pregnancy Category: X
During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes; modifying this physiologic change offers no known benefit and could result in fetal harm
Administration to rats during organogenesis and lactation resulted in hydrocephaly in offspring at 2-4 times clinical dose
Lactation: Unknown whether distributed in breast milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Growth hormone releasing factor (GRF) analog; stimulates growth hormone production and increases serum IGF-I; elicits anabolic and lipolytic actions;
Half-Life: 38 minutes
Peak Plasma Time: 9 min
Peak Plasma Concentration (Cmax): 2822.3 pg/mL
Vd: 10.5 L/kg (HIV infected patients); 9.4 L/kg (healthy adults)
Bioavailability: <4% (healthy adults)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs